Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Shares Outstanding (2022 - 2025)

Zentalis Pharmaceuticals has reported Shares Outstanding over the past 4 years, most recently at $69.1 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $69.1 million for Q4 2025, down 3.08% from a year ago — trailing twelve months through Dec 2025 was $69.1 million (down 3.08% YoY), and the annual figure for FY2025 was $69.1 million, down 3.08%.
  • Shares Outstanding for Q4 2025 was $69.1 million at Zentalis Pharmaceuticals, down from $72.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding for ZNTL hit a ceiling of $72.2 million in Q3 2025 and a floor of $45.6 million in Q1 2022.
  • Median Shares Outstanding over the past 4 years was $70.7 million (2023), compared with a mean of $66.3 million.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 30.4% in 2023 and later fell 3.08% in 2025.
  • Zentalis Pharmaceuticals' Shares Outstanding stood at $59.3 million in 2022, then increased by 19.38% to $70.8 million in 2023, then rose by 0.73% to $71.3 million in 2024, then decreased by 3.08% to $69.1 million in 2025.
  • The last three reported values for Shares Outstanding were $69.1 million (Q4 2025), $72.2 million (Q3 2025), and $72.1 million (Q2 2025) per Business Quant data.